Ono Enters into an Option Agreement with Reborna Biosciences for RNA-Targeting Small Molecule to treat CNS Disorders
Shots:
- Ono Pharmaceutical entered into an option agreement to obtain exclusive rights for identified small-molecule compounds developed by leveraging Reborna’s proprietary RNA-targeting drug discovery platform
- Furthermore, the companies will collaborate to discover small molecule drug candidates for mutually selected rare neurological disorders
- Upon exercising the option, Ono will gain exclusive worldwide rights to develop, manufacture, and commercialize identified small-molecule compounds, and Reborna will be eligible to receive an upfront payment, research funding, milestone payments tied to research, development, and sales achievements, and tiered royalties on net sales
Ref: Ono | Image: Ono & Reborna Biosciences
Related News:- Ono Pharma and Ionis Enter into License Agreement for Sapablursen to Treat Polycythemia Vera
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
An avid reader and a dedicated learner, Prince works as a Content Writer at PharmaShots. Prince possesses an exceptional quality of breaking down the barriers of words by simplifying the terms in digestible chunks to make content readable and comprehensible. Prince likes to read books and loves to spend his free time learning and upskilling himself.
